"10.1371_journal.pone.0082672","plos one","2013-12-11T00:00:00Z","Daniel H Johnson; Deborah Sutherland; Edward P Acosta; Husamettin Erdem; Danielle Richardson; David W Haas","Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America","Conceived and designed the experiments: DPS EPA DWH. Performed the experiments: DWH EPA DPS HE DR. Analyzed the data: DHJ EPA DWH. Wrote the manuscript: DHJ EPA DWH DPS HE DR.","DWH has received research grants to Vanderbilt University from Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and Merck. This work was primarily supported by a research grant from Merck (www.merck.com) to Vanderbilt University Medical Center (DWH, Principal Investigator). The Raltegravir used in this study is a product of Merck. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","12","Daniel H Johnson","DHJ",6,TRUE,3,5,3,6,TRUE,TRUE,FALSE,0,NA,FALSE
